157 related articles for article (PubMed ID: 27517321)
1. Increased expression of EHF contributes to thyroid tumorigenesis through transcriptionally regulating HER2 and HER3.
Lv Y; Sui F; Ma J; Ren X; Yang Q; Zhang Y; Guan H; Shi B; Hou P; Ji M
Oncotarget; 2016 Sep; 7(36):57978-57990. PubMed ID: 27517321
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of EHF via gene amplification contributes to the activation of HER family signaling and associates with poor survival in gastric cancer.
Shi J; Qu Y; Li X; Sui F; Yao D; Yang Q; Shi B; Ji M; Hou P
Cell Death Dis; 2016 Oct; 7(10):e2442. PubMed ID: 27787520
[TBL] [Abstract][Full Text] [Related]
3. TBX1 Functions as a Tumor Suppressor in Thyroid Cancer Through Inhibiting the Activities of the PI3K/AKT and MAPK/ERK Pathways.
Wang N; Li Y; Wei J; Pu J; Liu R; Yang Q; Guan H; Shi B; Hou P; Ji M
Thyroid; 2019 Mar; 29(3):378-394. PubMed ID: 30543152
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of EHF inhibited the proliferation, invasion and tumorigenesis of ovarian cancer cells.
Cheng Z; Guo J; Chen L; Luo N; Yang W; Qu X
Mol Carcinog; 2016 Jun; 55(6):1048-59. PubMed ID: 26258986
[TBL] [Abstract][Full Text] [Related]
5. PAX3 is a novel tumor suppressor by regulating the activities of major signaling pathways and transcription factor FOXO3a in thyroid cancer.
Liu W; Sui F; Liu J; Wang M; Tian S; Ji M; Shi B; Hou P
Oncotarget; 2016 Aug; 7(34):54744-54757. PubMed ID: 27458157
[TBL] [Abstract][Full Text] [Related]
6. N-cadherin promotes thyroid tumorigenesis through modulating major signaling pathways.
Da C; Wu K; Yue C; Bai P; Wang R; Wang G; Zhao M; Lv Y; Hou P
Oncotarget; 2017 Jan; 8(5):8131-8142. PubMed ID: 28042956
[TBL] [Abstract][Full Text] [Related]
7. ZIC1 is a putative tumor suppressor in thyroid cancer by modulating major signaling pathways and transcription factor FOXO3a.
Qiang W; Zhao Y; Yang Q; Liu W; Guan H; Lv S; Ji M; Shi B; Hou P
J Clin Endocrinol Metab; 2014 Jul; 99(7):E1163-72. PubMed ID: 24684457
[TBL] [Abstract][Full Text] [Related]
8. Positive Feedback Loops Between NrCAM and Major Signaling Pathways Contribute to Thyroid Tumorigenesis.
Zhang Y; Sui F; Ma J; Ren X; Guan H; Yang Q; Shi J; Ji M; Shi B; Sun Y; Hou P
J Clin Endocrinol Metab; 2017 Feb; 102(2):613-624. PubMed ID: 27732334
[TBL] [Abstract][Full Text] [Related]
9. E26 transformation (ETS)‑specific related transcription factor‑3 (ELF3) orchestrates a positive feedback loop that constitutively activates the MAPK/Erk pathway to drive thyroid cancer.
Chen H; Chen W; Zhang X; Hu L; Tang G; Kong J; Wang Z
Oncol Rep; 2019 Jan; 41(1):570-578. PubMed ID: 30365150
[TBL] [Abstract][Full Text] [Related]
10. EHF enhances malignancy by modulating AKT and MAPK/ERK signaling in non‑small cell lung cancer cells.
Gao L; Yang T; Zhang S; Liang Y; Shi P; Ren H; Hou P; Chen M
Oncol Rep; 2021 Jun; 45(6):. PubMed ID: 33907840
[TBL] [Abstract][Full Text] [Related]
11. Novel HER3/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cells.
Lakshmanan I; Seshacharyulu P; Haridas D; Rachagani S; Gupta S; Joshi S; Guda C; Yan Y; Jain M; Ganti AK; Ponnusamy MP; Batra SK
Oncotarget; 2015 Aug; 6(25):21085-99. PubMed ID: 26035354
[TBL] [Abstract][Full Text] [Related]
12. Metallothionein 1G functions as a tumor suppressor in thyroid cancer through modulating the PI3K/Akt signaling pathway.
Fu J; Lv H; Guan H; Ma X; Ji M; He N; Shi B; Hou P
BMC Cancer; 2013 Oct; 13():462. PubMed ID: 24098937
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.
Piechocki MP; Yoo GH; Dibbley SK; Lonardo F
Cancer Res; 2007 Jul; 67(14):6825-43. PubMed ID: 17638894
[TBL] [Abstract][Full Text] [Related]
14. HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3.
Ruiz-Saenz A; Dreyer C; Campbell MR; Steri V; Gulizia N; Moasser MM
Cancer Res; 2018 Jul; 78(13):3645-3658. PubMed ID: 29760043
[TBL] [Abstract][Full Text] [Related]
15. HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B.
Kirouac DC; Du J; Lahdenranta J; Onsum MD; Nielsen UB; Schoeberl B; McDonagh CF
PLoS Comput Biol; 2016 Apr; 12(4):e1004827. PubMed ID: 27035903
[TBL] [Abstract][Full Text] [Related]
16. SOSTDC1 inhibits follicular thyroid cancer cell proliferation, migration, and EMT via suppressing PI3K/Akt and MAPK/Erk signaling pathways.
Zhou Q; Chen J; Feng J; Xu Y; Zheng W; Wang J
Mol Cell Biochem; 2017 Nov; 435(1-2):87-95. PubMed ID: 28551845
[TBL] [Abstract][Full Text] [Related]
17. SIRT7 promotes thyroid tumorigenesis through phosphorylation and activation of Akt and p70S6K1 via DBC1/SIRT1 axis.
Li H; Tian Z; Qu Y; Yang Q; Guan H; Shi B; Ji M; Hou P
Oncogene; 2019 Jan; 38(3):345-359. PubMed ID: 30093629
[TBL] [Abstract][Full Text] [Related]
18. Intelectin 1 suppresses the growth, invasion and metastasis of neuroblastoma cells through up-regulation of N-myc downstream regulated gene 2.
Li D; Mei H; Pu J; Xiang X; Zhao X; Qu H; Huang K; Zheng L; Tong Q
Mol Cancer; 2015 Feb; 14():47. PubMed ID: 25889839
[TBL] [Abstract][Full Text] [Related]
19. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.
Balz LM; Bartkowiak K; Andreas A; Pantel K; Niggemann B; Zänker KS; Brandt BH; Dittmar T
J Pathol; 2012 Jun; 227(2):234-44. PubMed ID: 22262199
[TBL] [Abstract][Full Text] [Related]
20. Blockage of ETS homologous factor inhibits the proliferation and invasion of gastric cancer cells through the c-Met pathway.
Gu ML; Zhou XX; Ren MT; Shi KD; Yu MS; Jiao WR; Wang YM; Zhong WX; Ji F
World J Gastroenterol; 2020 Dec; 26(47):7497-7512. PubMed ID: 33384550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
